Genelux

Genelux Gross Margin

The Gross Margin of Genelux (GNLX) as of Oct 16, 2026 is -7,075.00 %. In the previous year, Gross Margin was -11,187.50 % — a change of -36.76% (higher).

Gross Margin

-7,075.00 %

YoY

-36.76%

Last updated:

Gross Margin of Genelux is 2025 -7,075.00 % . Gross Margin of Genelux was 2024 -11,187.50 % . It decreases by -36.76% higher compared to the previous year.

Genelux's gross margin stands at -7,075.0%, down from 91.3% several years earlier.

The Genelux Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2022
91.25 USD
Jan 1, 2023
-498.82 USD
Jan 1, 2024
-11,187.50 USD
Jan 1, 2025
-7,075.00 USD
The Genelux Gross Margin history
YEARGross MarginYoY
-7,075.00 %-36.76%
-11,187.50 %+2,142.78%
-498.82 %-646.63%
91.25 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genelux Stock analysis

What does Genelux do? Genelux Corp, trading under the ticker GNLX, is a biotechnology company based in Westlake Village, California, operating within the Health Care sector. The company has 25 employees and completed its initial public offering on January 26, 2023. Genelux focuses on developing oncolytic viral immunotherapies for solid tumor cancers. Its lead product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a modified vaccinia virus (VACV), a stable DNA virus with significant engineering potential. The company is currently advancing Olvi-Vec through Phase II clinical trials for platinum-resistant or refractory ovarian cancer (PRROC). Additionally, Genelux is developing a platform called Virus and Vaccine (Neoantigen)-Enhanced Adoptive Cell Therapy (V2ACT), which aims to enhance cancer neoantigen-specific T cell activity within tumors. The company also has an animal health product candidate, V-VET1, a genetically characterized, veterinary-grade oncolytic vaccinia virus that is a naturally attenuated isolate. Genelux's website is https://genelux.com/ and it is registered with the ISIN US36870H1032. The company's operations and product development are centered on innovative viral-based therapies for both human and animal health applications. Genelux is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genelux stock

Gross Margin of Genelux is -7,075.00 % in 2025.

Gross Margin of Genelux changed from -11,187.50 % to -7,075.00 %, representing a -36.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Genelux since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Genelux with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Genelux

All Key Metrics — Genelux